Jeffrey Hung
Stock Analyst at Morgan Stanley
(4.33)
# 329
Out of 5,182 analysts
233
Total ratings
48.59%
Success rate
18.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeffrey Hung
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Overweight | $150 → $136 | $86.96 | +56.39% | 15 | Mar 17, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $225 → $226 | $186.85 | +20.95% | 13 | Feb 25, 2026 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $90 → $92 | $68.90 | +33.53% | 14 | Feb 23, 2026 | |
| CTNM Contineum Therapeutics | Downgrades: Equal-Weight | $23 → $14 | $13.44 | +4.17% | 5 | Jan 8, 2026 | |
| NBIX Neurocrine Biosciences | Downgrades: Equal-Weight | $173 → $175 | $132.48 | +32.10% | 32 | Jan 8, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Overweight | $77 → $80 | $37.70 | +112.20% | 4 | Jan 6, 2026 | |
| CYTK Cytokinetics | Maintains: Overweight | $65 → $71 | $64.94 | +9.33% | 14 | Dec 23, 2025 | |
| BIOA BioAge Labs | Upgrades: Equal-Weight | $5 → $12 | $17.53 | -31.55% | 3 | Dec 8, 2025 | |
| ENGN enGene Holdings | Maintains: Overweight | $18 → $19 | $7.24 | +162.43% | 5 | Nov 12, 2025 | |
| CGON CG Oncology | Maintains: Overweight | $56 → $79 | $67.55 | +16.95% | 5 | Sep 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $28 | $14.92 | +87.67% | 7 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $4 → $2 | $17.12 | -88.32% | 4 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $13 | $4.89 | +165.85% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $102 → $108 | $14.45 | +647.40% | 5 | Jul 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $55 | $22.87 | +140.49% | 9 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $24 | $22.32 | +7.53% | 25 | May 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $85 | $65.82 | +29.14% | 6 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $27 | $39.67 | -31.94% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $3.98 | +779.40% | 1 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $10 → $4 | $3.68 | +8.70% | 10 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $1 → $4 | $1.30 | +207.69% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $14 | $5.40 | +159.26% | 3 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $5 | $3.67 | +36.24% | 1 | Jul 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $9 → $3 | $2.55 | +17.65% | 8 | Mar 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $10 | $1.40 | +614.29% | 3 | Jan 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $23 → $22 | $43.98 | -49.98% | 10 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $146 → $149 | $9.15 | +1,522.95% | 2 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $100 → $60 | $0.70 | +8,481.24% | 5 | Aug 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $6 | $3.97 | +51.13% | 9 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $696 → $648 | $11.03 | +5,774.89% | 6 | May 8, 2020 |
Rhythm Pharmaceuticals
Mar 17, 2026
Maintains: Overweight
Price Target: $150 → $136
Current: $86.96
Upside: +56.39%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Overweight
Price Target: $225 → $226
Current: $186.85
Upside: +20.95%
PTC Therapeutics
Feb 23, 2026
Maintains: Overweight
Price Target: $90 → $92
Current: $68.90
Upside: +33.53%
Contineum Therapeutics
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $23 → $14
Current: $13.44
Upside: +4.17%
Neurocrine Biosciences
Jan 8, 2026
Downgrades: Equal-Weight
Price Target: $173 → $175
Current: $132.48
Upside: +32.10%
Crinetics Pharmaceuticals
Jan 6, 2026
Maintains: Overweight
Price Target: $77 → $80
Current: $37.70
Upside: +112.20%
Cytokinetics
Dec 23, 2025
Maintains: Overweight
Price Target: $65 → $71
Current: $64.94
Upside: +9.33%
BioAge Labs
Dec 8, 2025
Upgrades: Equal-Weight
Price Target: $5 → $12
Current: $17.53
Upside: -31.55%
enGene Holdings
Nov 12, 2025
Maintains: Overweight
Price Target: $18 → $19
Current: $7.24
Upside: +162.43%
CG Oncology
Sep 17, 2025
Maintains: Overweight
Price Target: $56 → $79
Current: $67.55
Upside: +16.95%
Aug 18, 2025
Maintains: Overweight
Price Target: $35 → $28
Current: $14.92
Upside: +87.67%
Aug 18, 2025
Downgrades: Equal-Weight
Price Target: $4 → $2
Current: $17.12
Upside: -88.32%
Aug 12, 2025
Maintains: Equal-Weight
Price Target: $17 → $13
Current: $4.89
Upside: +165.85%
Jul 17, 2025
Upgrades: Overweight
Price Target: $102 → $108
Current: $14.45
Upside: +647.40%
Jul 14, 2025
Maintains: Overweight
Price Target: $65 → $55
Current: $22.87
Upside: +140.49%
May 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $24
Current: $22.32
Upside: +7.53%
Mar 7, 2025
Assumes: Overweight
Price Target: $85
Current: $65.82
Upside: +29.14%
Mar 7, 2025
Assumes: Overweight
Price Target: $27
Current: $39.67
Upside: -31.94%
Jul 26, 2024
Initiates: Overweight
Price Target: $35
Current: $3.98
Upside: +779.40%
Dec 19, 2023
Downgrades: Underweight
Price Target: $10 → $4
Current: $3.68
Upside: +8.70%
Dec 19, 2023
Upgrades: Equal-Weight
Price Target: $1 → $4
Current: $1.30
Upside: +207.69%
Aug 4, 2023
Maintains: Equal-Weight
Price Target: $14
Current: $5.40
Upside: +159.26%
Jul 11, 2023
Reiterates: Equal-Weight
Price Target: $5
Current: $3.67
Upside: +36.24%
Mar 20, 2023
Maintains: Equal-Weight
Price Target: $9 → $3
Current: $2.55
Upside: +17.65%
Jan 30, 2023
Downgrades: Underweight
Price Target: $50 → $10
Current: $1.40
Upside: +614.29%
Nov 2, 2022
Maintains: Equal-Weight
Price Target: $23 → $22
Current: $43.98
Upside: -49.98%
May 11, 2022
Maintains: Equal-Weight
Price Target: $146 → $149
Current: $9.15
Upside: +1,522.95%
Aug 13, 2021
Downgrades: Underweight
Price Target: $100 → $60
Current: $0.70
Upside: +8,481.24%
Apr 19, 2021
Maintains: Equal-Weight
Price Target: $7 → $6
Current: $3.97
Upside: +51.13%
May 8, 2020
Maintains: Overweight
Price Target: $696 → $648
Current: $11.03
Upside: +5,774.89%